H.C. Wainwright Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)

August 10, 2026 6:41 AM

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $74.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found